[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Galantamine.]
[L04AA27, fingolimod, Galantamine may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The metabolism of Succinylcholine can be decreased when combined with Galantamine.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sulpiride.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Galantamine.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Terbutaline.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Galantamine can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Apomorphine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Galantamine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Eribulin.]
[N05CA19, thiopental, The therapeutic efficacy of Thiopental can be decreased when used in combination with Galantamine.]
[N05AC02, thioridazine, The metabolism of Galantamine can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Galantamine.]
[G04BE06, moxisylyte, Galantamine may increase the neuromuscular blocking activities of Moxisylyte.]
[B01AC05, ticlopidine, The metabolism of Galantamine can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, Galantamine may increase the bradycardic activities of Timolol.]
[N02AX02, tramadol, The therapeutic efficacy of Tramadol can be decreased when used in combination with Galantamine.]
[N06AF04, tranylcypromine, The metabolism of Galantamine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Galantamine.]
[S01BA05, triamcinolone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Triamcinolone.]
[A03AB12, mepenzolate, The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Galantamine.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Galantamine.]
[D07AC02, fluclorolone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluclorolone.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Galantamine.]
[R03BA07, mometasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Galantamine.]
[C02BA01, trimethaphan, Galantamine may increase the neuromuscular blocking activities of Trimethaphan.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Galantamine.]
[R06AC04, tripelennamine, The metabolism of Galantamine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Galantamine.]
[A03BB01, butylscopolamine, The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Galantamine.]
[J01FA08, troleandomycin, The metabolism of Galantamine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Galantamine can be decreased when combined with Vilazodone.]
[M03AA02, tubocurarine, Galantamine may increase the neuromuscular blocking activities of Tubocurarine.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Galantamine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Galantamine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Galantamine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Galantamine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Galantamine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Galantamine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Galantamine can be decreased when combined with Vinblastine.]
[S01AA13, fusidic acid, The metabolism of Galantamine can be decreased when combined with Fusidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Galantamine can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Galantamine.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Galantamine.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ibandronate.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ziprasidone.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Galantamine.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Tolterodine.]
[C07AB03, atenolol, Galantamine may increase the bradycardic activities of Atenolol.]
[J02AC03, voriconazole, The metabolism of Galantamine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The therapeutic efficacy of Atracurium can be decreased when used in combination with Galantamine.]
[S01FA01, atropine, The therapeutic efficacy of Atropine can be decreased when used in combination with Galantamine.]
[H02AB11, prednylidene, The therapeutic efficacy of Galantamine can be decreased when used in combination with Prednylidene.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Galantamine.]
[A08AA11, lorcaserin, The metabolism of Galantamine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Galantamine can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Galantamine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Galantamine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.]
[H02AA01, aldosterone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Aldosterone.]
[L01EX05, regorafenib, Galantamine may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, The therapeutic efficacy of Barbital can be decreased when used in combination with Galantamine.]
[J05AE04, nelfinavir, The metabolism of Galantamine can be decreased when combined with Nelfinavir.]
[C08CA13, lercanidipine, Lercanidipine may increase the bradycardic activities of Galantamine.]
[N06DA02, donepezil, Galantamine may increase the bradycardic activities of Donepezil.]
[L04AA29, tofacitinib, Galantamine may increase the bradycardic activities of Tofacitinib.]
[R06AC06, thonzylamine, The therapeutic efficacy of Thonzylamine can be decreased when used in combination with Galantamine.]
[G04BD10, darifenacin, The metabolism of Galantamine can be decreased when combined with Darifenacin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Galantamine can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Galantamine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Galantamine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Galantamine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the bradycardic activities of Galantamine.]
[G03XC05, ospemifene, The metabolism of Galantamine can be decreased when combined with Ospemifene.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Galantamine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Galantamine.]
[M01AH01, celecoxib, The metabolism of Galantamine can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The metabolism of Galantamine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Galantamine.]
[L01EC02, dabrafenib, The serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Galantamine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Galantamine.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Bepridil.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Galantamine.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Galantamine.]
[J05AP05, simeprevir, The metabolism of Galantamine can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Galantamine.]
[C07AB04, acebutolol, Galantamine may increase the bradycardic activities of Acebutolol.]
[A16AA07, metreleptin, The metabolism of Galantamine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Galantamine can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, Galantamine may increase the bradycardic activities of Betaxolol.]
[L04AC11, siltuximab, The metabolism of Galantamine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Galantamine may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Galantamine.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Olodaterol.]
[D11AA01, glycopyrronium, The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Galantamine.]
[A16AX10, eliglustat, The metabolism of Galantamine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Galantamine can be decreased when combined with Oritavancin.]
[V04CX03, methacholine, The risk or severity of adverse effects can be increased when Galantamine is combined with Methacholine.]
[N04AA02, biperiden, The metabolism of Galantamine can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Galantamine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Galantamine.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Galantamine.]
[L04AC10, secukinumab, The metabolism of Galantamine can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Galantamine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Galantamine can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, The therapeutic efficacy of Difemerine can be decreased when used in combination with Galantamine.]
[C01EB17, ivabradine, Galantamine may increase the bradycardic activities of Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Galantamine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Galantamine.]
[A04AD14, rolapitant, The metabolism of Galantamine can be decreased when combined with Rolapitant.]
[A02BC03, lansoprazole, The metabolism of Galantamine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Galantamine.]
[J02AC05, isavuconazole, The metabolism of Galantamine can be decreased when combined with Isavuconazole.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Galantamine.]
[N05CA05, aprobarbital, The therapeutic efficacy of Aprobarbital can be decreased when used in combination with Galantamine.]
[L01XX52, venetoclax, The metabolism of Galantamine can be decreased when combined with Venetoclax.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Galantamine.]
[C08CA01, amlodipine, Amlodipine may increase the bradycardic activities of Galantamine.]
[N01BB01, bupivacaine, The metabolism of Galantamine can be decreased when combined with Bupivacaine.]
[C07AA19, bupranolol, Galantamine may increase the bradycardic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Galantamine can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Buserelin.]
[N05BE01, buspirone, The metabolism of Galantamine can be decreased when combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Galantamine may increase the bradycardic activities of Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Azatadine.]
[S01GX07, azelastine, The metabolism of Galantamine can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Galantamine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Galantamine can be decreased when combined with Ribociclib.]
[R03CC12, bambuterol, Galantamine may increase the neuromuscular blocking activities of Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Galantamine.]
[S01HA02, benoxinate, Galantamine may increase the neuromuscular blocking activities of Oxybuprocaine.]
[R05DB01, benzonatate, Galantamine may increase the neuromuscular blocking activities of Benzonatate.]
[J05AE09, tipranavir, The metabolism of Galantamine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Galantamine.]
[L04AB02, infliximab, The metabolism of Galantamine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Galantamine can be decreased when combined with Midostaurin.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Galantamine is combined with Bethanechol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Delafloxacin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Galantamine is combined with Acetylcholine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Galantamine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Vorinostat.]
[C07AB07, bisoprolol, Galantamine may increase the bradycardic activities of Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Galantamine can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Galantamine may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Galantamine.]
[R03BA02, budesonide, The therapeutic efficacy of Galantamine can be decreased when used in combination with Budesonide.]
[N05CA03, butobarbital, The therapeutic efficacy of Butobarbital can be decreased when used in combination with Galantamine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Galantamine.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Acetyldigoxin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Acrivastine.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Galantamine is combined with Carbamoylcholine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Galantamine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Galantamine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, The therapeutic efficacy of Camylofin can be decreased when used in combination with Galantamine.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Carbinoxamine.]
[C07AG02, carvedilol, Galantamine may increase the bradycardic activities of Carvedilol.]
[N03AX24, cannabidiol, The metabolism of Galantamine can be decreased when combined with Cannabidiol.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Encorafenib.]
[C07AB08, celiprolol, Galantamine may increase the bradycardic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Galantamine.]
[L01XX62, ivosidenib, The metabolism of Galantamine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Galantamine.]
[N03AX17, stiripentol, The metabolism of Galantamine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Galantamine.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Galantamine.]
[N01BA04, chloroprocaine, Galantamine may increase the neuromuscular blocking activities of Chloroprocaine.]
[R06AA06, chlorphenoxamine, The therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Galantamine.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Inotersen.]
[R03BB08, revefenacin, The therapeutic efficacy of Revefenacin can be decreased when used in combination with Galantamine.]
[L04AA39, emapalumab, The metabolism of Galantamine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of adverse effects can be increased when Galantamine is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Cilostazol.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Triclabendazole.]
[J01FA09, clarithromycin, The metabolism of Galantamine can be decreased when combined with Clarithromycin.]
[N05BA09, clobazam, The metabolism of Galantamine can be decreased when combined with Clobazam.]
[H02AB14, cloprednol, The therapeutic efficacy of Galantamine can be decreased when used in combination with Cloprednol.]
[L04AB01, etanercept, The metabolism of Galantamine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The therapeutic efficacy of Galantamine can be decreased when used in combination with Cortivazol.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Cicletanine.]
[L01EJ02, fedratinib, The metabolism of Galantamine can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Galantamine can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Galantamine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Galantamine.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Galantamine.]
[H02AB13, deflazacort, The therapeutic efficacy of Galantamine can be decreased when used in combination with Deflazacort.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Galantamine.]
[N03AX25, cenobamate, The serum concentration of Galantamine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Galantamine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Galantamine.]
[R06AB02, dexchlorpheniramine, The metabolism of Galantamine can be decreased when combined with Dexchlorpheniramine.]
[M01AX21, diacetylrhein, The metabolism of Galantamine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Galantamine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Galantamine can be decreased when combined with Amprenavir.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Galantamine.]
[N02CC06, eletriptan, The metabolism of Galantamine can be decreased when combined with Eletriptan.]
[C08CA16, clevidipine, Galantamine may increase the neuromuscular blocking activities of Clevidipine.]
[C01BD07, dronedarone, The metabolism of Galantamine can be decreased when combined with Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Chlorcyclizine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Galantamine.]
[A03AA08, dihexyverine, The therapeutic efficacy of Dihexyverine can be decreased when used in combination with Galantamine.]
[D07XB03, fluprednidene, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluprednidene.]
[G04BD09, trospium, The therapeutic efficacy of Trospium can be decreased when used in combination with Galantamine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fostemsavir.]
[P01BB01, proguanil, The metabolism of Galantamine can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Galantamine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The metabolism of Oliceridine can be decreased when combined with Galantamine.]
[P01BA01, chloroquine, The metabolism of Galantamine can be decreased when combined with Chloroquine.]
[R06AB04, chlorpheniramine, The metabolism of Galantamine can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Galantamine can be decreased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Chlorprothixene.]
[M03BB03, chlorzoxazone, The metabolism of Galantamine can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Galantamine can be decreased when combined with Cholecalciferol.]
[N06BX18, vinpocetine, Galantamine may increase the bradycardic activities of Vinpocetine.]
[B06AC06, berotralstat, The metabolism of Galantamine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Galantamine can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Relugolix.]
[P03AX07, abametapir, The serum concentration of Galantamine can be increased when it is combined with Abametapir.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Felbamate.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Flumequine.]
[R03BA03, flunisolide, The therapeutic efficacy of Galantamine can be decreased when used in combination with Flunisolide.]
[S02BA08, fluocinolone acetonide, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluocinolone acetonide.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Galantamine.]
[L03AB10, peginterferon alfa-2b, The metabolism of Galantamine can be decreased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Galantamine can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Galantamine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Galantamine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Galantamine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Clemastine.]
[N06AX25, St. John's wort extract, The metabolism of Galantamine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Galantamine can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Clofazimine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Galantamine.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Galantamine.]
[C01EB24, mavacamten, The serum concentration of Galantamine can be decreased when it is combined with Mavacamten.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Granisetron.]
[N05AH02, clozapine, The metabolism of Galantamine can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Galantamine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Galantamine may increase the neuromuscular blocking activities of Cocaine.]
[L04AC21, bimekizumab, The metabolism of Galantamine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Galantamine can be decreased when combined with Codeine.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Galantamine.]
[A03AB10, hexocyclium, The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Galantamine.]
[A03BB06, homatropine methylbromide, The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Galantamine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Desflurane.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Galantamine.]
[J01FA15, telithromycin, The metabolism of Galantamine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The therapeutic efficacy of Galantamine can be decreased when used in combination with Ciclesonide.]
[R06AX27, desloratadine, The therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Galantamine.]
[J02AC02, itraconazole, The metabolism of Galantamine can be decreased when combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Emedastine.]
[L01EA01, imatinib, The serum concentration of Galantamine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Galantamine can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Galantamine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Levocabastine.]
[S01BA03, cortisone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Cortisone.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lomefloxacin.]
[C08CA11, manidipine, The metabolism of Galantamine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, The therapeutic efficacy of Mebeverine can be decreased when used in combination with Galantamine.]
[C07AA14, mepindolol, Galantamine may increase the bradycardic activities of Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Meprednisone.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Adenosine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Galantamine.]
[C04AX01, cyclandelate, Galantamine may increase the bradycardic activities of Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Cyclizine.]
[N05AD03, metylperon, The metabolism of Galantamine can be decreased when combined with Melperone.]
[N06AX07, minaprine, The metabolism of Minaprine can be decreased when combined with Galantamine.]
[S01XA18, cyclosporine, The metabolism of Galantamine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Galantamine can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Galantamine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Moexipril.]
[C03XA02, conivaptan, The metabolism of Galantamine can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Galantamine can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Galantamine can be decreased when combined with Danazol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Galantamine.]
[C07AB12, nebivolol, Galantamine may increase the bradycardic activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Galantamine can be decreased when combined with Nefazodone.]
[M03AC11, cisatracurium, The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Galantamine.]
[N06AB10, escitalopram, The serum concentration of Galantamine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Solifenacin.]
[N06AA01, desipramine, The metabolism of Galantamine can be decreased when combined with Desipramine.]
[D07XC02, desoximetasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Desoximetasone.]
[H02AA03, desoxycorticosterone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Desoxycortone.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Oxaliplatin.]
[S03BA01, dexamethasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Dexamethasone.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Galantamine.]
[G04BD04, oxybutynin, The metabolism of Galantamine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Galantamine can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Galantamine.]
[L04AB04, adalimumab, The metabolism of Galantamine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Galantamine can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The metabolism of Galantamine can be decreased when combined with Amphetamine.]
[R05DA09, dextromethorphan, The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Galantamine.]
[N06AB05, paroxetine, The metabolism of Galantamine can be decreased when combined with Paroxetine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Galantamine.]
[A03AA07, dicyclomine, The therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pinaverium.]
[A03AB14, pipenzolate, The therapeutic efficacy of Pipenzolate can be decreased when used in combination with Galantamine.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Galantamine.]
[C08CA03, isradipine, The metabolism of Galantamine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Difluocortolone.]
[A03AB11, poldine, The therapeutic efficacy of Poldine can be decreased when used in combination with Galantamine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Galantamine.]
[J05AE08, atazanavir, The metabolism of Galantamine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Galantamine.]
[C08DB01, diltiazem, The metabolism of Galantamine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dimenhydrinate.]
[R06AB03, dimethindene, The therapeutic efficacy of Dimetindene can be decreased when used in combination with Galantamine.]
[M02AX03, dimethyl sulfoxide, The metabolism of Galantamine can be decreased when combined with Dimethyl sulfoxide.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Diphenhydramine.]
[B01AC07, dipyridamole, The therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.]
[A03FA02, cisapride, The metabolism of Galantamine can be decreased when combined with Cisapride.]
[N05AL04, remoxipride, The metabolism of Galantamine can be decreased when combined with Remoxipride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Disulfiram.]
[S02AA12, rifamycin SV, The metabolism of Galantamine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Galantamine can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Levocetirizine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Galantamine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Galantamine.]
[C01EB18, ranolazine, The serum concentration of Galantamine can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Salmeterol.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Galantamine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Galantamine can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Galantamine.]
[N06AB06, sertraline, The metabolism of Galantamine can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Droperidol.]
[C10AA01, simvastatin, The metabolism of Galantamine can be decreased when combined with Simvastatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Sultopride.]
[C07AB13, talinolol, Galantamine may increase the bradycardic activities of Talinolol.]
[H01AA01, corticotropin, The therapeutic efficacy of Galantamine can be decreased when used in combination with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Galantamine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Terodiline.]
[C07AA16, tertatolol, Galantamine may increase the bradycardic activities of Tertatolol.]
[G04BD01, emepronium, The therapeutic efficacy of Emepronium can be decreased when used in combination with Galantamine.]
[M01AG02, tolfenamic acid, Galantamine may increase the bradycardic activities of Tolfenamic acid.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Galantamine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Toremifene.]
[A03AB08, tridihexethyl, The therapeutic efficacy of Tridihexethyl can be decreased when used in combination with Galantamine.]
[H02CA01, trilostane, The therapeutic efficacy of Galantamine can be decreased when used in combination with Trilostane.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Triptorelin.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Galantamine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Galantamine.]
[L01CA04, vinorelbine, The metabolism of Galantamine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, Galantamine may increase the neuromuscular blocking activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Galantamine can be decreased when combined with Venlafaxine.]
[C08CA12, mepirodipine, The metabolism of Galantamine can be decreased when combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Galantamine can be decreased when combined with Zolpidem.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Zonisamide.]
[C02AC02, guanfacine, Galantamine may increase the bradycardic activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Moricizine.]
[N02CA02, ergotamine, The metabolism of Galantamine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Valproic acid.]
[S01AA17, erythromycin, The metabolism of Galantamine can be decreased when combined with Erythromycin.]
[H05BX01, cinacalcet, The metabolism of Galantamine can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Galantamine can be decreased when combined with Ethambutol.]
[R03BA05, fluticasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Galantamine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Galantamine.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Galantamine.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Galantamine.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Galantamine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Galantamine.]
[R06AX12, terfenadine, The metabolism of Galantamine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Galantamine can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Galantamine can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Famotidine.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Galantamine can be decreased when combined with Fenfluramine.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Galantamine.]
[N02AB03, fentanyl, Galantamine may increase the bradycardic activities of Fentanyl.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Salbutamol.]
[N07AX03, cevimeline, The risk or severity of adverse effects can be increased when Galantamine is combined with Cevimeline.]
[G04BD02, flavoxate, The therapeutic efficacy of Flavoxate can be decreased when used in combination with Galantamine.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Galantamine.]
[J02AC01, fluconazole, The metabolism of Galantamine can be decreased when combined with Fluconazole.]
[H02AA02, fludrocortisone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fludrocortisone.]
[D07XB01, flumethasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Flumethasone.]
[N07CA03, flunarizine, Galantamine may increase the bradycardic activities of Flunarizine.]
[D07AC08, fluocinonide, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluocinonide.]
[H02AB03, fluocortolone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluocortolone.]
[S01CB05, fluorometholone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluorometholone.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fluorouracil.]
[N06AB03, fluoxetine, The serum concentration of Galantamine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Galantamine can be decreased when combined with Fluphenazine.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Fluspirilene.]
[M03AA01, alcuronium, The therapeutic efficacy of Alcuronium can be decreased when used in combination with Galantamine.]
[J05AE10, darunavir, The metabolism of Galantamine can be decreased when combined with Darunavir.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Amisulpride.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pipemidic acid.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluticasone furoate.]
[M03AC02, gallamine, The therapeutic efficacy of Gallamine can be decreased when used in combination with Galantamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Gallopamil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dasatinib.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Methsuximide.]
[N01AH02, alfentanil, Galantamine may increase the bradycardic activities of Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lapatinib.]
[N05CM18, dexmedetomidine, The metabolism of Galantamine can be decreased when combined with Dexmedetomidine.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dofetilide.]
[C02CA04, doxazosin, The metabolism of Galantamine can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Galantamine.]
[C07AB09, esmolol, Galantamine may increase the bradycardic activities of Esmolol.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Goserelin.]
[P01BX01, halofantrine, The metabolism of Galantamine can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Quetiapine can be decreased when used in combination with Galantamine.]
[L01CE02, irinotecan, Galantamine may increase the neuromuscular blocking activities of Irinotecan.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Losartan.]
[N05CA16, hexobarbital, The therapeutic efficacy of Hexobarbital can be decreased when used in combination with Galantamine.]
[J05AG01, nevirapine, The metabolism of Galantamine can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Galantamine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, Galantamine may increase the bradycardic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Hydrocortisone.]
[G04BD06, propiverine, The therapeutic efficacy of Propiverine can be decreased when used in combination with Galantamine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Hydroxyzine.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Galantamine.]
[N01AH03, sufentanil, Galantamine may increase the bradycardic activities of Sufentanil.]
[N06AA02, imipramine, The metabolism of Galantamine can be decreased when combined with Imipramine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Terlipressin.]
[R01AD07, tixocortol, The therapeutic efficacy of Galantamine can be decreased when used in combination with Tixocortol.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Tizanidine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Indapamide.]
[N06AX17, milnacipran, The metabolism of Galantamine can be decreased when combined with Milnacipran.]
[A03AA30, piperidolate, The therapeutic efficacy of Piperidolate can be decreased when used in combination with Galantamine.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Galantamine is combined with Varenicline.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Galantamine.]
[C10AA06, cerivastatin, The metabolism of Galantamine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Anagrelide.]
[C07AA01, alprenolol, Galantamine may increase the bradycardic activities of Alprenolol.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Galantamine.]
[N06AF05, iproniazid, The metabolism of Galantamine can be decreased when combined with Iproniazid.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Isoflurane.]
[N04BX02, entacapone, The metabolism of Galantamine can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Galantamine can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The metabolism of Galantamine can be decreased when combined with Reboxetine.]
[L04AC07, tocilizumab, The metabolism of Galantamine can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The metabolism of Galantamine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Galantamine.]
[L04AA24, abatacept, The metabolism of Galantamine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Galantamine can be decreased when combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Nalidixic acid.]
[C07AG01, labetalol, Galantamine may increase the bradycardic activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Amantadine.]
[N03AX18, lacosamide, Galantamine may increase the bradycardic activities of Lacosamide.]
[S02DA01, lidocaine, The metabolism of Galantamine can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Lidoflazine.]
[N02CA07, lisuride, The metabolism of Galantamine can be decreased when combined with Lisuride.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Loperamide.]
[C10AA02, lovastatin, The metabolism of Galantamine can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Galantamine can be decreased when combined with Temsirolimus.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the bradycardic activities of Galantamine.]
[L01EA03, nilotinib, The metabolism of Galantamine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Maprotiline.]
[C02BB01, mecamylamine, The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.]
[R06AE05, meclizine, The therapeutic efficacy of Meclizine can be decreased when used in combination with Galantamine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Galantamine.]
[N03AB04, mephenytoin, The metabolism of Galantamine can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, The therapeutic efficacy of Methylphenobarbital can be decreased when used in combination with Galantamine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Dolasetron.]
[H01CB03, lanreotide, Galantamine may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Galantamine can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The metabolism of Metamfetamine can be decreased when combined with Galantamine.]
[A03AB07, methantheline, The therapeutic efficacy of Methantheline can be decreased when used in combination with Galantamine.]
[N03AA30, metharbital, The therapeutic efficacy of Metharbital can be decreased when used in combination with Galantamine.]
[H03BB02, methimazole, The metabolism of Galantamine can be decreased when combined with Methimazole.]
[N05AA02, methotrimeprazine, The metabolism of Galantamine can be decreased when combined with Methotrimeprazine.]
[N02BG09, methoxyflurane, The metabolism of Methoxyflurane can be decreased when combined with Galantamine.]
[C02AB01, methyldopa, Galantamine may increase the bradycardic activities of Methyldopa.]
[V04CG05, methylene blue, The metabolism of Galantamine can be decreased when combined with Methylene blue.]
[H02AB04, methylprednisolone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Methylprednisolone.]
[D07AC14, methylprednisolone aceponate, The therapeutic efficacy of Galantamine can be decreased when used in combination with Methylprednisolone aceponate.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Metoclopramide.]
[C07AB02, metoprolol, The metabolism of Galantamine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Metronidazole.]
[C01BB02, mexiletine, The metabolism of Galantamine can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Galantamine.]
[S02AA13, miconazole, The metabolism of Galantamine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Galantamine.]
[C01CA17, midodrine, Midodrine may increase the bradycardic activities of Galantamine.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mifepristone.]
[L01XX23, mitotane, The metabolism of Galantamine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Galantamine can be decreased when combined with Lisdexamfetamine.]
[C01BD01, amiodarone, The metabolism of Galantamine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Galantamine.]
[A04AA05, palonosetron, The metabolism of Galantamine can be decreased when combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Galantamine can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pazopanib.]
[M03AC03, vecuronium, The therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.]
[N05CA02, amobarbital, The therapeutic efficacy of Amobarbital can be decreased when used in combination with Galantamine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Galantamine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Galantamine.]
[N03AB05, fosphenytoin, The metabolism of Galantamine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Galantamine may increase the bradycardic activities of Nadolol.]
[V03AB15, naloxone, The metabolism of Galantamine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Galantamine can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The metabolism of Galantamine can be decreased when combined with Amphetamine.]
[N06AX21, duloxetine, The metabolism of Galantamine can be decreased when combined with Duloxetine.]
[N01AH06, remifentanil, Galantamine may increase the bradycardic activities of Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The metabolism of Galantamine can be decreased when combined with Desvenlafaxine.]
[C10AD02, niacin, The metabolism of Galantamine can be decreased when combined with Niacin.]
[C08CA04, nicardipine, The metabolism of Galantamine can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Nicergoline can be decreased when combined with Galantamine.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Galantamine is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Nimodipine.]
[C08CA07, nisoldipine, Nisoldipine may increase the bradycardic activities of Galantamine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Nitrendipine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Norfloxacin.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Galantamine.]
[G02CA02, nylidrin, Galantamine may increase the bradycardic activities of Nylidrin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Galantamine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Galantamine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Galantamine can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Galantamine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Galantamine.]
[P02BA02, oxamniquine, The metabolism of Galantamine can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Galantamine may increase the bradycardic activities of Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Galantamine can be decreased when combined with Oxycodone.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Galantamine.]
[A03AB03, oxyphenonium, The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Galantamine.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Galantamine.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Asenapine.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Papaverine.]
[H02AB05, paramethasone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Galantamine.]
[G04BD11, fesoterodine, The therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.]
[C07AA23, penbutolol, Galantamine may increase the bradycardic activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Galantamine can be increased when combined with Pentobarbital.]
[C08EX02, perhexiline, The metabolism of Galantamine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Galantamine can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Galantamine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Galantamine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Galantamine can be increased when combined with Phenobarbital.]
[N03AB02, phenytoin, The metabolism of Galantamine can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Galantamine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Levofloxacin.]
[C08CX01, mibefradil, The metabolism of Galantamine can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Galantamine is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Galantamine.]
[C07AA03, pindolol, Galantamine may increase the bradycardic activities of Pindolol.]
[J05AE01, saquinavir, The metabolism of Galantamine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Galantamine can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Galantamine can be decreased when combined with Pipotiazine.]
[A02BX03, pirenzepine, The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Grepafloxacin.]
[N02CX01, pizotyline, The therapeutic efficacy of Pizotifen can be decreased when used in combination with Galantamine.]
[J05AG02, delavirdine, The metabolism of Galantamine can be decreased when combined with Delavirdine.]
[L04AC08, canakinumab, The metabolism of Galantamine can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Galantamine can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, Galantamine may increase the bradycardic activities of Practolol.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Prajmaline.]
[S03BA02, prednisolone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Prednisolone.]
[H02AB07, prednisone, The therapeutic efficacy of Galantamine can be decreased when used in combination with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Prenylamine.]
[P01BA03, primaquine, The metabolism of Galantamine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Galantamine can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Galantamine.]
[S01HA05, procaine, Galantamine may increase the neuromuscular blocking activities of Procaine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Prochlorperazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Galantamine.]
[G03DA04, progesterone, The metabolism of Galantamine can be decreased when combined with Progesterone.]
[N05AA03, promazine, The therapeutic efficacy of Promazine can be decreased when used in combination with Galantamine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Promethazine.]
[C01BC03, propafenone, The metabolism of Galantamine can be decreased when combined with Propafenone.]
[A03AB05, propantheline, The therapeutic efficacy of Propantheline can be decreased when used in combination with Galantamine.]
[N05CM06, propiomazine, The therapeutic efficacy of Propiomazine can be decreased when used in combination with Galantamine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Galantamine can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Galantamine may increase the bradycardic activities of Propranolol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Galantamine.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Aripiprazole.]
[A03AB15, diphemanil, The therapeutic efficacy of Diphemanil can be decreased when used in combination with Galantamine.]
[A03AB09, isopropamide, The therapeutic efficacy of Isopropamide can be decreased when used in combination with Galantamine.]
[S01FA03, methscopolamine, The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Galantamine.]
[N05CA07, talbutal, The therapeutic efficacy of Talbutal can be decreased when used in combination with Galantamine.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Galantamine can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Galantamine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Galantamine can be decreased when combined with Ranitidine.]
[J04AB02, rifampin, The metabolism of Galantamine can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Roxithromycin.]
[S01FA02, scopolamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.]
[N05CA06, secobarbital, The therapeutic efficacy of Secobarbital can be decreased when used in combination with Galantamine.]
[N04BD01, selegiline, The metabolism of Galantamine can be decreased when combined with Selegiline.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Galantamine.]
[D07AB02, hydrocortisone butyrate, The therapeutic efficacy of Galantamine can be decreased when used in combination with Hydrocortisone butyrate.]
[H02CA04, levoketoconazole, The metabolism of Galantamine can be decreased when combined with Levoketoconazole.]
[R03BB01, ipratropium bromide, The therapeutic efficacy of Ipratropium can be decreased when used in combination with Galantamine.]
